Fig. 4

Patient’s response matched with PDOs drug assays, RTO7 in the upper panel and mCTO50 in the lower panel. Each CT scan response evaluation is compared with corresponding treatment administered in the corresponding PDOs. ≠ means discordant response, = means concordant response. Mo(s): months in terms of progression-free survival; St: stage; FOLFIRI: 5-fluorouracil and irinotecan; FOLFOX: 5-fluorouracil and oxaliplatin; FOLFOXIRI: 5-fluorouracil, oxaliplatin and irinotecan; BSC: best supportive care; SD: stable disease; PR: partial response; PD: progressive disease; R1: microscopic residual tumor